Abstract
The field of psychopharmacology has its sources in a number of different medical disciplines involved with the function of the brain. In the area of pharmacology, a major contribution has been made by the study of those drugs that are collectively known as psychotropic agents. The term “psychotropic” is used to describe a drug that turns or changes the mind, following quite literally from the Greek stemψυχη meaning soul, mind, or understanding, and τρεπειν, to turn. A sizable proportion of our present pharmacopoea contains medicines designed to play a role in the changing or modification of a person’s mood or mental state. A classification of these materials into families defined by the nature of the mental state change evoked is a useful way of defining the subdivision known as “psychotomimetic drugs.” An historically interesting procedure was established by Lewin (1924), who characterized these drugs in five subdivisions according to the nature of their action.
This is a preview of subscription content, log in via an institution to check access.
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Abood, L. G., 1968, The psychotomimetic glycolate esters, in Drugs Affecting the Central Nervous System (A. Burger, ed.), pp. 127–167, Marcel Decker, New York.
Abramson, H. A., 1959, Lysergic acide diethylamide (LSD-25): XXIX. The response index as a measure of threshold activity of psychotropic drugs in man, J. Psych. 48:65–78.
Abramson, H. A., and Rolo, A., 1967, Comparison of LSD with methysergide and psilocybin on test subjects, in The Use of LSD in Psychotherapy and Alcoholism (H. A. Abramson, ed.), pp. 53–73, Bobbs Merrill, New York.
Agurell, S., 1969a, Cactaceae alkaloids. I. Lloydia 32:206–216.
Agurell, S., 1969b, Identification of alkaloid intermediates by gas chromatography-mass spectrometry. I. Potential mescaline precursors in Trichocereus species, Lloydia 32:40–45.
Agurell, S., Bruhn, J. G., Lundstrom, J., and Svensson, U., 1971, Cactaceae alkaloids. X. Alkaloids of Trichocereus species and some other cactii, Lloydia 34:183–187.
Aldous, F. A. B., Barrass, B. C., Brewster, K., Buxton, D. A., Green, D. M., Pinder, R. M., Rich, P., Skeels, M., and Tutt, H. J., 1974, Structure-activity relationships in psychotomimetic phenylalkylamines, J. Med. Chem. 17:1100–1111.
Alles, G. A., 1933, The comparative physiological actions of dl-β-phenylisopropylamines. I. Pressor effects and toxicity. J. Pharm. Exp. Ther. 47:339–354.
Alles, G. A., 1959, Some relations between chemical structure and physiological action of mescaline and related compounds, in Neuropharmacology, Trans. Fourth Conf. (H. A. Abramson, ed.), pp. 181-268, J. Macy, Jr. Foundation.
Anderson, G., III, Kollman, P., Jacob, P., III, Shulgin, A. T., and Castagnoli, N., Jr., 1977, The synthesis and pharmacological evaluation of ring substituted 1-phenyl-2-aminopropanes, paper presented at ACS 173rd Natl. Meeting, New Orleans, March 21–25.
Andreoli, V. M., Danieli, B., and Tonon, G. C., 1973, Significance of methoxylated derivatives in amphetamine psychosis, Riv. Farmacol. Ter. 4(4):1a–21a (CA:81:20757c).
Angrist, B. M., and Gershon, S., 1970, The phenomenology of experimentally induced amphetamine psychosis—preliminary observations, Biol. Psychiat. 2:95–107.
Angrist, B. M., Schweitzer, J. W., Gershon, S., and Friedhoff, A. J., 1970a, Mephentermine psychosis: Misuse of the wyamine inhealer, Am. J. Psychiat. 126:1315–1317.
Angrist, B. M., Schweitzer, J. W., Friedhoff, A. J., and Gershon, S., 1970b, Investigation of p-methoxyamphetamine excretion in amphetamine induced psychosis, Nature 225:651–662.
Angrist, A., Rotrosen, J., and Gershon, S., 1974, Assessment of tolerance to the hallucinogenic effects of DOM. Psychopharmacologia 36:203–207.
Anonymous, 1959, Therapeutic compositions containing 1-(2,4-dimethylphenyl)-2-aminopropane, Br. Patent 819,129 (CA: 54:10245).
Anonymous, 1970, Listing of MDA (methylenedioxyamphetamine), MMDA (methoxymethylenedioxyamphetamine), TMA (trimethoxyamphetamine), JB-318 (N-ethyl-3(2)(4)-piperidylbenzilate), and JB-336 (N-methyl-3(2)(4)-piperidylbenzilate) and their salts as subject to control, Fed. Reg. 35:7069-7070.
Anonymous, 1973a, Physician’s Desk Reference, p. 1319, Medical Economics Company, Oradell, New Jersey.
Anonymous, 1973b, para-Methoxyamphetamine (PMA), Microgram 6:66-71.
Anonymous, 1976, Proposed revised aggregate production quota for 1976; 2,5-dimethoxyamphetamine. Fed. Reg. 41:21208.
Antun, F., Smythies, J. R., Benington, F., Morin, R. D., Barfknecht, C. F., and Nichols, D. E., 1971, Native fluorescence and hallucinogenic potency of some amphetamines, Experientia 27:62–63.
Bailey, K., 1972, The mass spectra of dimethoxyamphetamine hydrochlorides, Anal. Chim. Acta 60:287–292.
Bailey, K., Beckstead, H. D., Legault, D., and Verner, D., 1974a, Identification of 2-, 3-, and 4-methoxyamphetamines and 2-, 3-, and 4-methylamphetamines, J.A.O.A.C. 57:1134–1143.
Bailey, K., Legault, D., and Verner, D., 1974b, Spectroscopic identification of dimethoxyamphetamines, J.A.O.A.C. 57:70–78.
Bailey, K., By, A. W., Legault, D., and Verner, D., 1975, Identification of the N-methylated analogs of the hallucinogenic amphetamines and some isomers, J.A.O.A.C. 58:62–69.
Bailey, K., Gagné, D. R., and Pike, R. K., 1976, Investigation and identification of the bromination products of dimethoxyamphetamines, J.A.O.A.C. 59:1162–1169.
Baker, R. W., Chothia, C., Pauling, P., and Weber, H. P., 1973, Molecular structures of hallucinogenic substances: Lysergic acid diethylamide, psilocybin and 2,4,5-trimethoxyamphetamine, Mol. Pharmacol. 9:23–32.
Barfknecht, C. F., and Nichols, D. E., 1971, Potential psychotomimetics. Bromomethoxyamphetamines, J. Med. Chem. 14:370–372.
Barfknecht, C. F., Nichols, D. E., and Dunn, W. J., 1975, Correlation of psychotomimetic activity of phenethylamines and amphetamines with 1-octanol-water partition coefficients, J. Med. Chem. 18:208–210.
Beaton, J. M., Smythies, J. R., Benington, F., Morin, R. D., and Clark, L. C., 1968, Behavioral effects of some 4-substituted amphetamines Nature 220:800–801.
Bell, D. S., 1965, Comparison of amphetamine psychosis and schizophrenia, Br. J. Psychiatry 111:701–717.
Benington, F., Morin, R. D., and Clark, L. C., 1954, Mescaline analogs, I. 2,4,6-Trimethoxy-β-phenethylamines, J. Org. Chem. 19:11–16.
Benington, F., Morin, R. D., Clark, L. C., and Fox, R. P., 1958, Psychopharmacological activity of ring-and side chain-substituted beta-phenethylamines, J. Org. Chem. 23:1979–1984.
Benington, F., Morin, R. D., Beaton, J., Smythies, J. R., and Bradley, R. J., 1973, Comparative effects of stereoisomers of hallucinogenic amphetamines, Nature 242:185–186.
Beringer, K., 1927, Der meskalinrauche. Seine Geschichte und Erscheinungsweise, Verlag Julius Springer, Berlin.
Biniecki, S., and Krajewski, E., 1960, Preparation of DL-1-(3,4-methylenedioxyphenyl)-2-(methylamine)propane and DL-1-(3,4-dimethoxyphenyl)-2-(methylamino)-propane, Acta Polon. Pharm. 17:421.
Biniecki, S., and Muszynski, E., 1953, Synthesis of amphetamine derivatives, Acta Polon. Pharm. 10:211–221.
Bosin, T. R., Campaigne, E., Dinner, A., Rogers, R. B., and Maickel, R. P., 1976, Comparative toxicological studies of indole, benzo(b)thiophene, and 1-methylindole derivatives, J. Toxico. Environ. Health 1:515–520.
Braun, G., and Shulgin, A. T., 1976, Unpublished data.
Braun, J. G., 1975, Pharmacognostic Studies of Peyote and Related Psychoadive Cadi, Doctoral thesis, Uppsala University.
Braun, U., and Kalbhen, D. A., 1972, Nachweis der Bildung psychotroper Amphetamin-Derivate aus Inhaltsstoffen der Muskatness, Deut. Med. Woch. 97:1614.
Braun, U., and Kalbhen, D. A., 1973, Evidence for the biogenic formation of amphetamine derivatives from components of nutmeg, Pharmacology 9:312–316.
Braun, U., Shulgin, A. T., Braun, G., and Sargent, T., III, 1977, Brain visualization agents: The synthesis and body distribution of several 131I-labelled CNS-active drugs, J. Med. Chem. in press.
Bravo, H. H., 1967, Una revisión del género Lophophora, Cad. Sucul. Mex. 12:8.
Brawley, P., and Duffield, J. C., 1972, The pharmacology of hallucinogens, Pharm. Rev. 24:31–66.
Brimblecombe, R. W., 1963, Effects of psychotropic drugs on the open field behavior in rats, Psychopharmacologia 4:139–147.
Brimblecombe, R. W., 1967, Hyperthermic effects of some tryptamine derivatives in relation to their behavioral activity, Int. J. Neuropharm. 6:423–429.
Brimblecombe, R. W., and Pinder, R. M., 1975, Hallucinogenic Agents, Scientechnica, Bristol.
Brimblecombe, R. W., Downing, D. F., Green, D. M., and Hunt, R. R., 1964, Some pharmacological effects of a series of tryptamine derivatives, Br. J. Pharmacol. 23:43–54.
Brown, H. D., 1958, Antitussive compositions, U.S. Patent 2,820,739 (Jan. 21, 1958).
Brown, W. T., McGeer, P. L., and Moser, I., 1968, Lack of psychotomimetic effect of paramethoxyphenylethylamine and 3,4-dimethoxyphenethylamine in man, Can. Psychiat. J. 13:91–92.
Bruckner, V., 1933, Über das Pseudonitrosit des Asarons, J. Prakt. Chem. 138:268–274.
Bueno, O. F. A., 1975, Mescaline and homoveratrylamine as discriminative stimuli in rats, Acta Physiol. Lat. Am. 25:77–79.
Burger, A., and Foggio, R. D., 1956, Nuclear substituted 3,4-dihydroxyphenethylamines and related derivatives, J.A.C.S. 78:4419–4422.
Buu-Hoi, N. P., and Petit, L., 1960, Some homologs of α,α-dimethyl-β-phenethylamine, J. Org. Chem. 25:726–728.
Campaigne, E., and Knapp, D. R., 1970, Benzo(b)thiophene derivatives. XIV. Derivatives of naphtho(1,8-c)thiophene, J. Heterocycl. Chem. 7:107.
Carlini, E. A., Silva, M. T. A., Cesare, L. C., and Endo, R. M., 1967, Effects of chronic administration of beta-(3,4-dimethoxyphenyl)-ethylamine and beta-(3,4,5-trimethoxyphenyl)-ethylamine on the climbing rope performance of rats, Med. Pharmacol. Exp. 17:534–542.
Carlsson, A., Corrodi, H., and Magnusson, T., 1963, Basische Derivate des 4,5,6-Trimethoxyindols und des 3,4,5-Trimethoxyphenols, Helv. Chim. Acta 46:1231–1235.
Carlsson, A., Lindquist, M., Wysokowski, J., Corrodi, H., and Junggren, U., 1970, Substituted meta-tyramines as brain monoamine depletors, Acta Pharm. Suecica 7:293–302.
Cerletti, A., 1959, in Neuro-Psychopharmacology (P. B. Bradley, P. Deniker, and C. Radouco-Thomas, eds.), Elsevier, Amsterdam.
Charalampous, K. D., and Tansey, L. W., 1967, Metabolic fate of β-(3,4-dimethoxyphenyl)-ethylamine in man, J. Pharm. Exp. Ther. 155:318–329.
Charalampous, K. D., Orengo, A., Walker, K. E., and Kinross-Wright, J., 1964, Metabolic fate of β-(3,4,5-trimethoxyphenyl)-ethylamine (mescaline) in humans: Isolation and identification of 3,4,5-trimethoxyphenylacetic acid, J. Pharm. Exp. Ther. 145:242–246.
Charalampous, K. D., Walker, K. E., and Kinross-Wright, J., 1966, Metabolic fate of mescaline in man, Psychopharmacologia 9:48–63.
Cheng, H. C., Long, J. P., Nichols, D. E., and Barfknecht, C. F., 1974, Effects of paramethoxyamphetamine (PMA) on the cardiovascular system of the dog, Arch. Int. Pharmacol. Ther. 212:83–88.
Chothia, C., and Pauling, P., 1969, On the conformations of hallucinogenic molecules and their correlations, Proc. Natl. Acad. Sci. 63:1063–1070.
Cimbura, G., 1974, PMA deaths in Ontario, J. Can. Med. Assoc. 110:1263–1267.
Clark, L. C., Benington, F., and Morin, R. D., 1965, The effects of ring-methoxy groups on biological deamination of phenethylamines, J. Med. Chem. 8:353–355.
Cohen, I., Fischer, J. F., and Vogel, W. H., 1974, Physiological disposition of beta-phenethylamine, 2,4,5-trimethoxyphenethylamine, 2,3,4,5,6-pentamethoxyphenethylamine, and beta-hydroxymescaline in rat brain, liver, and plasma, Psychopharmacologia 36:77–84.
Cohen, S., 1960, Lysergic acid diethylamide: Side effects and complications. J. Nerv. Mental. Dis. 130:30–40.
Connell, P. H., 1958, Amphetamine Psychosis, Maudsley Monographs No. 5, Chapman and Hall, London.
Cook, L., and Fellows, E. J., 1961, Anorexigenic preparation and method of curbing the appetite, U.S. Patent 2,974,148 (March 7, 1961).
Cordova, V., 1974, Analytical data on 4-methyl amphetamine sulfate, Microgram 7:196–208.
Corne, S. J., and Pickering, R. W., 1967, A possible correlation between drug-induced hallucinations in man and a behavioral response in mice, Psychopharmacologia 11:65–78.
Coutts, R. T., and Malicky, J. L., 1973, The synthesis of some analogs of the hallucinogen 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM), Can. J. Chem. 51:1402–1409.
Dallacker, F., 1969, Derivatives of methylenedioxybenzene. XXVIII. Reactions of the dimethoxymethylenedioxybenzaldehydes, Monat Chem. 100:742–747.
Davis, V. E., and Walsh, M. J., 1970, Alcohol, amines, and alkaloids: A possible biochemical basis for alcohol addiction, Science 167:1005–1007.
Delay, J., 1959, Classification of psychotropic drugs, in Psychopharmacology Frontiers (N. S. Klein, ed.), Churchill, London.
Deniker, P., Peron-Magnan, P., Guillou, C. E. L., and Hanus, M., 1971, Essais cliniques d’une amphétamine antidépressive originale, la d-l-para-chloro-N-methylamphétamine ou Ro 4 6861, Therapie 26:219–226.
De Vries, J. X., Moyna, P., Dias, V., Agurell, S., and Bruhn, J. G., 1971, Alcaloides de cactos del Uruguay, Rev. Latinoam. Quim. 2:21–23.
De Zan, P., 1971, Analysis and identification of 2,5-dimethoxyamphetamine, Microgram 4:5–11.
De Zorsi, C., and Cavalli, A., 1974, Un nuovo allucinogeno: La MMA (P-metil-M-metossi anfetamina), Zacchia 10:3–11.
Dittrich, A., 1971, Alteration of behavioral changes induced by 3,4,5-trimethoxyphenylethylamine (mescaline) by pretreatment with 2,4,5-trimethoxyphenylethylamine. A self-experiment, Psychopharmacologia 21:229–237.
Dixon, W. E., 1899, The physiological action of the alkaloids derived from Anhalonium lewinii, J. Physiol. 25:69–86.
Dyer, D. C., Nichols, D. E., Rusterholz, D. B., and Barfknecht, C. F., 1973, Comparative effects of stereoisomers of psychotomimetic phenylisopropylamines, Life Sci. 13:885–896.
Elkes, C., Elkes, J., and Mayer-Gross, W., 1955, Hallucinogenic drugs, Lancet 268:719.
Ellis, H., 1898, Mescal, a new artificial paradise, Ann. Rep. Smithsonian Inst. 1897:537–548, U.S. Govt. Printing Office.
Epstein, D., Gunn, J. A., and Virden, C. J., 1932, The action of some amines related to adrenalin. I. Methoxyphenethylamines, J. Physiol. 76:224–246.
Ernst, A. M., 1962, Phenomena of the hypokinetic rigid type caused by O-methylation of dopamine in the para-position, Nature 193:178–179.
Ernst, A. M., 1965, Relation between the structure of certain methoxyphenylethylamine derivatives and the occurrence of a hypokinetic rigid syndrome, Psychopharmacologia 7:383–390.
Faillace, L. A., Snyder, S. H., and Weingartner, H., 1970, 2,5-Dimethoxy-4-methylamphetamine: Clinical evaluation of a new hallucinogenic drug, J. Nerv. Mental. Dis. 150:119–126.
Fairchild, M. D., 1963, Some Central Nervous System Effects of Four Phenylsubstituted Amphetamine Derivatives, Ph.D. thesis, U.C.L.A.
Fairchild, M. D., Alles, G. A., Jenden, D. J., and Mickey, M. R., 1967, The effects of mescaline, amphetamine, and four ring-substituted amphetamine derivatives on spontaneous brain electrical activity in the cat, Int. J. Neuropharm. 6:151–167.
Forrest, J. E., and Heacock, R. A., 1972, Nutmeg and mace, the psychotropic spices from Myristica fragrans, Lloydia 35:440–449.
Friedhoff, A. J., and Hollister, L. E., 1966, Comparison of the metabolism of 3,4-dimethoxyphenylethylamine and mescaline in humans, Biochem. Pharmacol. 15:269–273.
Friedhoff, A. J., and Schweitzer, J. W., 1968, An effect of N-acetyldimethoxyphenethylamine, Dis. Nerv. System 29:455–456.
Friedhoff, A. J., and Van Winkle, E., 1962, Isolation and characterization of a compound from the urine of schizophrenics, Nature 194:867–868.
Fuller, R. W., Hines, C. W., and Mills, J., 1965, Lowering of brain serotonin levels by chloramphetamines, Biochem. Pharmacol. 14:483–488.
Fuller, R. W., Baker, J. C., Perry, K. W., and Molloy, B. B., 1975, Comparison of 4-chloro-, 4-bromo-and 4-fluoroamphetamin in rats. Drug levels in brain and effects on brain serotonin metabolism, Neuropharmacology 14:739–746.
Furst, P. T. (ed.), 1972, Flesh of the Gods, the Ritual Use of the Hallucinogens, Praeger, New York.
Gaston, T. R., and Rasmussen, G. T., 1972, Identification of 3,4-methylenedioxymethamphetamine, Microgram 5:60.
Greenberg, J. R., and Lustig, N., 1966, Misuse of Dristan inhaler, N.Y.J. Med. 66:613–617.
Griffith, J. D., Cavanaugh, J. H., Held, J., and Oates, J. A., 1970, Experimental psychosis induced by the administration of d-amphetamine, in Amphetamines and Related Compounds (E. Costa and S. Garrattini, eds.), pp. 897–904, Raven Press, New York.
Guenther, E., 1952, Oil of calamus, in The Essential Oils, Vol. VI, pp. 109–117, Van Nostrand, New York.
Gunn, J. A., Gurd, M. R., and Sachs, I., 1939, The action of some amines related to adrenaline: Methoxyphenylisopropylamines, J. Physiol. 95:485–500.
Haase, H. J., 1966, Neuroleptika, Tranquilizer und Antidepressiva in Klinik und Praxis, Janssen, Dusseldorf.
Hall, C. S., 1934, Emotional behavior in the rat. I. Defecation and urination as measures of individual differences in emotionality, J. Comp. Psych. 18:385–403.
Hambourger, W. E., and Jamieson, R. B., Jr., 1936, Comparison of the pressor effects of some new alkyl derivatives of β-phenylethylamines, J. Pharm. Exp. Ther. 58:53–61.
Hardman, H. F., Haavik, C. O., and Seevers, M. H., 1973, Relationship of the structure of mescaline and seven analogs to toxicity and behavior in five species of laboratory animals, Toxicol. Appl. Pharm. 25:299–309.
Harris, S. C., and Worley, R. C., 1957, Analgesic properties of xylopropamine, Proc. Soc. Exp. Biol. Med. 95:212–215.
Harrison, S. D., Bosin, T. R., and Maickel, R. P., 1974, Metabolism of the benzo(b)thiophene analog of N,N-dimethyltryptamine in vivo and in vitro in the rat. Application of organic chemical and spectroscopic techniques to problems of drug metabolism, Drug Metabol. Disp. 2:228–236.
Harvey, J. A., and McMaster, S. E., 1976, Neurotoxic action of para-chloroamphetamine in the rat as revealed by Nissl and silver stains, Psychopharmacol. Bull. 12(3):62–64.
Heffter, A., 1898, Ueber pellote, Arch. Exp. Path. Pharmakol. 40:385–429.
Hellpach, W., 1941, Funktionelle Differenzierung der “psychischen Stimulantein,” Deut. Med. Wochen. 67:1358.
Hernñndez, F., 1651, Nova Plantarum, Animalium et Mineralium Mexicanorum Historia, B. Deuersini and Z. Masotti, Rome.
Hey, P., 1947, The synthesis of a new homolog of mescaline, Quart. J. Pharm. Pharmacol. 20:129–134.
Ho, B. T., 1975, Metabolism of hallucinogens in brain and other tissues, Psychopharmacol. Bull. 11:61–62.
Ho, B. T., Tansey, L. W., Balster, R. L., An, R., McIsaac, W. M., and Harris, R. T., 1970a, Amphetamine analogs. II. Methylated phenylethylamines, J. Med. Chem. 13:134–135.
Ho, B. T., McIsaac, W. M., An, R., Tansey, L. W., Walker, K. E., Englert, L. F., Jr., and Noel, M. B., 1970b, Analogs of alpha-methylphenethylamine (amphetamine). I. Synthesis and pharmacological activity of some methoxy and/or methyl analogs, J. Med. Chem. 13:26–30.
Ho, B. T., Estevez, V., and Fritschie, G. E., 1971a, The fate of 2,5-dimethoxy-4-methylamphetamine (STP, DOM) in monkey and rat brains, Brain Res. 29:166–169.
Ho, B. T., Estevez, V., Tansey, L. W., Englert, L. F., Creaven, P. J., and McIsaac, W. M., 1971b, Analogs of amphetamine. 5. Studies of excretory metabolites of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) in rats, J. Med. Chem. 14:158–160.
Hoch, P. H., 1951, Experimentally produced psychoses, Am. J. Psychiat. 107:607–611.
Hoffer, A., and Osmond, H., 1967, The Hallucinogens, pp. 55–56. Academic Press, New York.
Hofmann, A., 1959, Psychotomimetic drugs: Chemical and pharmacological aspects, Acta Physiol. Pharmacol. Neerl. 8:240–258.
Hofmann, A., 1960, Psychotomimetics: Chemical, pharmacological and medical aspects, Svensk. Kern. Tidskr. 72:723–747.
Hofmann, A., 1968, Psychotomimetic agents, in Drugs Affecting the Nervous System, Vol. 2 (A. Burger, ed.), pp. 169–235, Marcel Dekker, New York.
Hollister, L. E., and Friedhoff, A. J., 1966, Effects of 3,4-dimethoxyphenylethylamine in man, Nature 210:1377–1378.
Hollister, L. E., Macnicol, M. F., and Gillespie, H. K., 1969, An hallucinogenic amphetamine analog (DOM) in man, Psychopharmacologia 14:62–73.
Horii, A., and Inoi, T., 1957, Syntheses of arylalkylamines. IV. Syntheses of α-methyl-2-alkoxyphenethylamines and nuclear substituted derivatives. Yakugaku Zasshi 77:1095–1100 (CA 52:5318i).
Horita, A., and Dille, J. M., 1954, The pyretogenic effect of lysergic acid diethylamide, Science 120:1100–1101.
Hunt, R. R., and Brimblecombe, R. W., 1967, Synthesis and biological activity of some ring-substituted tryptamines, J. Med. Chem. 10:646–648.
Idänpään-Heikkilä, J. E., and McIsaac, W. M., 1970, 2,5-Dimethoxy-4-methylamphetamine tissue distribution and neurochemical action, Biochem. Pharmacol. 19:935–937.
Idänpään-Heikkilä, J. E., McIsaac, W. M., and Ho, B. T., 1969, Relation of pharmacological and behavioral effects of a hallucinogenic amphetamine to distribution in rat brain, Science 164:1085–1087.
Idänpään-Heikkilä, J. E., McIsaac, W. M., and Ho, B. T., 1969, Relation of pharmacological and behavioral effects of a hallucinogenic amphetamine to distribution in rat brain, Science 164:1085–1087.
Isbell, H., Miner, E. J., and Logan, C. R., 1959, Relationships of psychotomimetic to anti-serotonin potencies of congeners of lysergic acid diethylamide (LSD-25), Psychopharmacologia 1:20–28.
Jacob, J., and Lafille, C., 1963, Pharmacological characterization and detection of hallucinogenic substances. Hyperthermic activity in rabbits, Arch. Int. Pharmacodyn. 145:528–545.
Jacob, J., Loiseau, G., Echinard-Garin, P., and Barthelemy, C., 1962, Recherche d’equivalents expérimentaux au pouvoir hallucinogène, Med. Exp. 7:296–304.
Jacob, P., III, Anderson, G., III, Meshul, C. K., Shulgin, A. T., and Castagnoli, N., Jr., 1977, The monomethylthio analogs of 1-(2,4,5-trimethoxyphenyl)-2-aminopropane, J. Med. Chem. in press.
Jansen, M. P. J. M., 1931, β-2,4,5-Trimethoxyphenylethylamine, an isomer of mescaline, Rec. Trav. Chim. 50:291–312.
Jolly, F., 1896, Ueber Pellotin als Schlafmittel, Deut. Med. Wochen. 22:375–376.
Kalbhen, D. A., and Braun, G., 1973, A new concept and further support for the importance and occurrence of 3,4-dimethoxyphenethylamine (DMPEA) in urine of schizophrenic patients, Pharmacology 9:52–56.
Kalbhen, D. A., Sargent, T., Shulgin, A. T., Braun, G., Stauffer, H., Kusubov, N., and Nohr, M. L., 1974, Human pharmacodynamics of the psychodysleptic 4-bromo-2,5-dimethoxy-phenylisopropylamine labelled with 82Br, I.R.C.S. 2:1091.
Rang, S., and Green, J. P., 1970, Correlation between activity and electronic state of hallucinogenic amphetamines, Nature 226:645.
Kapatia, G. J., and Fayez, M. B. E., 1973, The chemistry of peyote alkaloids, Lloydia 36:9–35.
Keaton, R., 1973, Additional information of 4-methylamphetamine, Microgram 6:98–100.
Kelley, J. M., and Adamson, R. H., 1973, A comparison of common interatomic distances in serotonin and some hallucinogenic drugs, Pharmacology 10:28–31.
Klüver, H., 1928, Mescal, and Mechanisms of Hallucinations, Univ. of Chicago Press, Chicago. [Phoenix Science Series, 1966.]
Knoll, E., and Wisser, H., 1976, Radioimmunologische Bestimmung von 3,4-Dimethoxyphenyläthylamine im Urin, Clin. Chim. Acta 68:327–332.
Knoll, J., Vizi, E. S., and Knoll, B., 1970, Pharmacological studies on para-bromomethamphetamine (V-111) and LSD, Acta Physiol. Acad. Sci. Hung. 37:151–170.
Kulkarni, A. S., 1973, Scratching response induced in mice by mescaline and related amphetamine derivatives, Biol. Psychiat. 6:177–180.
Kumbar, M., and Siva Sankar, D. V., 1973, Quantum chemical studies on drug actions. III. Correlation of hallucinogenic and anti-serotonin activity of lysergic acid derivatives with quantum chemical data, Res. Comm. Chem. Path. Pharm. 6:65–100.
La Barre, W., 1969, The Peyote Cult, Schlocken, New York.
Lehmann, H. E., 1958, Tranquillizers and other psychotropic drugs in clinical practice, Can. Med. Assoc. J. 79:701.
Lehmann, H. E., 1959, Classification and terminology of psychotropic drugs, in Psychopharmacological Frontiers (N. J. Klein ed.), Churchill, London.
Lewin, L., 1924, Phantasica, Narcotic and Stimulating Drugs, Engl. transl. 2nd ed., Rouledge and Kegan, 1964.
Lipman, V. C., Shurrager, P. S., and Abood, L. G., 1963, Effect of anticholinergic psychotomimetics on motor activity and body temperature, Arch. Int. Pharmacodyn. 146:174–191.
Loman, J., Myerson, P. G., and Myerson, A., 1941, Experimental pharmacology of post-encephalitic Parkinson’s disease, Trans. Am. Neurol. Assoc. 67:201–203.
Luduena, F. P., 1935, Sobre la farmacologia de la tricocereina, alcaloide del Trichocereus terscheki (Parm.) Britton and Rose, Rev. Soc. Arg. Biol. 11:604–610.
Luduena, F. P., 1936, Pharmacologie de la trichocereine, alkaloïde du Trichocereus terscheki (Parm.) Britton et Rose, CTS Biol. 121:368–369.
Lundström, J., 1971a, Biosynthesis of mescaline and tetrahydroisoquinoline alkaloids in Lophophora williamsii (Lern.) Coult. Occurrence and biosynthesis of catecholamine and other intermediates, Acta Chem. Scand. 25:3489–3499.
Lundström, J., 1971b, Biosynthesis of tetrahydroisoquinoline alkaloids in Lophophora williamsii (Lern.) Coult., Acta Pharm. Suicida 8:485.
Lundström, J., and Agurell, S., 1968, Gas chromatography of peyote alkaloids. A new peyote alkaloid, J. Chromatogr. 36:105–108.
McLaughlin, J. L., and Paul, A. G., 1965, Presence of hordenine in Lophophora williamsii, J. Pharm. Sci. 54:661.
McLaughlin, J. L., and Paul, A., 1966, Identification of N-methyltyramine derivatives in Lophophora williamsii, Lloydia 29:315–327.
Mannich, C., and Jacobsohn, W., 1910, Über Oxyphenyl-alkylamine und Dioxyphenyl-Alkylamine, Chem. Ber. 43:189–197.
Marriott, A., and Rachlin, C. K., 1971, Peyote, Crowell, New York.
Marsh, D. F., and Herring, D. A., 1950, The pharmacological activity of the ring methyl substituted phenylisopropylamines, J. Pharm. Exp. Ther. 100:298–308.
Matin, S. B., Callery, P. S., Zweig, J. S., O’Brien, A., Rapaport, R., and Castagnoli, N., Jr., 1974, Stereochemical aspects and metabolic formation in the in vivo metabolism of the psychotomimetic amine 1-(2,5-dimethoxy-4-methyl)-2-aminopropane, J. Med. Chem. 17:877–882.
Menon, M. K., Tseng, L.-F., and Loh, H. H., 1976, Pharmacological evidence for the central serotonergic effects of monomethoxyamphetamines, J. Pharm. Exp. Ther. 197:272–279.
Meyers, F. H., Rose, A. J., and Smith, D. E., 1968, Incidents involving the Haight-Ashbury population and some uncommonly used drugs, J. Psychedelic Drugs 1:139–146.
Michaux, R., and Verly, W. G., 1963, Action catalepsigene des ethers methylique des mono-et polyphenolamines, Life Sci. 3:175–183.
Midha, K. K., 1974, Identification of two in vivo metabolites of 3,4-methylenedioxyamphetamine by gas-liquid chromatography-mass spectrometry, J. Chromatogr. 101:210–214.
Mitoma, C., 1970, Metabolic studies on trimethoxyamphetamines, Proc. Soc. Exp. Biol. Med. 134:1162–1164.
Monroe, R. R., and Drell, H. J., 1947, Oral use of stimulants obtained from inhalers, J. Am. Med. Soc. 135:909–915.
Morin, R. D., Benington, F., Mitchell, S. R., Beaton, J. M., Bradley, R. J., and Smythies, J. R., 1975, The behavioral effects of 2,5-dimethoxy-4-alkyl amphetamines, Experientia 31:93–95.
Morishita, H., Nakano, S., Satoda, K., and Inoi, T., 1956, beta-(o-Alkoxy-phenyl)isopropylamines, Patent (Japan) 8021 (CA 52:11918e).
Naranjo, C., 1967, Psychotropic Properties of the Harmala Alkaloids. Ethnopharmacologic Search for Psychoactive Drugs (D. Efron, ed.), USGPO Public Health Service Publication #1645, pp. 385-391.
Naranjo, C., 1973, The Healing Journey: New Approaches to Consciousness, Pantheon, New York.
Naranjo, C., Shulgin, A. T., and Sargent, T., 1967, Evaluation of 3,4-methylenedioxyamphetamine (MDA) as an adjunct of psychotherapy, Med. Pharmacol. Exp. 17:359–364.
Neal, J. M., Sato, P. T., Howalt, W. N., and McLaughlin, J. L., 1972, Peyote alkaloids: Identification in the mexican cactus Pelecyphora aselliformis, Science 176:1131.
Nichols, D. E., and Shulgin, A. T., 1976, Sulfur analogs of psychotomimetic amines, J. Pharm. Sci. 65:1554–1556.
Nichols, D. E., Shulgin, A. T., and Dyers, D. C., 1977, Directional lipophilic character in in vitro serotonin activity in a series of psychotomimetic derivatives, Psychopharmacol. Commun., in press.
Osmond, H., 1956, A review of the clinical effects of psychotomimetic agents, Ann. N.Y. Acad. Sci. 66:418–434.
Oswald, E. O., Fishbein, L., and Corbett, B. J., 1969, Metabolism of naturally occurring propenyl benzene derivatives. I. Chromatographic separation of ninhydrin-positive materials from rat urine, J. Chromatogr. 45:437–445.
Oswald, E. O., Fishbein, L., Corbett, B. J., and Walker, M. P., 1971a, Identification of tertiary amino-methylenedioxypropiophenones as urinary metabolites of safrole in the rat and guinea pig, Biochem. Biophys. Acta 230:237–247.
Oswald, E. O., Fishbein, L., Corbett, B. J., and Walker, M. P., 1971nb, Urinary excretion of tertiary aminomethoxymethylenedioxypropiophenones as metabolites of myristicin in the rat and guinea pig, Biochem. Biophys. Acta 244:322–328.
Pahnke, W. N., and Richards, W. A., 1966, Implications of LSD and experimental mysticism, J. Rel. Health 5:175.
Parli, C. J., and Schmidt, B., 1975, Metabolism of 4-chloroamphetamine to 3-chloro-4-hydroxyamphetamine in rat: Evidence for an in vivo “NIH shift” of chlorine, Res. Commun. Chem. Path. Pharmacol. 10:601–604.
Paul, A., 1973, Biosynthesis of the peyote alkaloids, Lloydia 36:36–45.
Peretz, D. I., Smythies, J. R., and Gibson, W. C., 1955, A new hallucinogen: 3,4,5-trimethoxyphenyl-beta-aminopropane (with notes on a stroboscopic phenomenon), J. Mental. Sci. 101:317–329.
Perry, T. L., Hansen, S., and Macintyre, L., 1964, Failure to detect 3,4-dimethoxyphenylethylamine in the urine of schizophrenics, Nature 202:519–520.
Pletscher, A., Burkard, W. P., Bruderer, H., and Gey, K. F., 1963, Decrease in cerebral 5-HT and 5-hydroxyindoleacetic acid by an aryl alkyl amine, Life Sci. 2:828–833.
Poisson, M. J., 1960, Présence de mescaline dans une cactacée péruvienne, Ann. Pharm. Franc. 18:764–765.
Prinzmetal, M., and Bloomberg, W., 1935, The use of benzedrine for the treatment of narcolepsy, J. Am. Med. Assoc. 105:2051–2054.
Reti, L., 1939, Nuovi alcaloidi di cactacee argentine, Atti X Congr. Int. Chim., Roma 5:396–405.
Reti, L., and Castrillón, J. A., 1951, Cactus alkaloids. I. Trichocereus terscheckii (Parmentier) Britton and Rose, J. Am. Chem. Soc. 73:1767–1769.
Riceberg, L. J., and Vunakis, H. V., 1975, Estimation of β-3,4-dimethoxyphenethylamine and related compounds in urine extracts by radioimmunoassay, Biochem. Pharm. 24:259–265.
Rouhier, A., 1926, Monographie du Peyotl Echinocactus williamsii Lem, Lucien Decluma, Lonsle-Saunier.
Sanders-Bush, E., Bushing, J. A., and Sulser, F., 1972, Long-term effects of p-chloroamphetamine on tryptophan hydroxylase activity and on the levels of 5-hydroxytryptamine and 5-hydroxyindole acetic acid in brain, Eur. J. Pharmacol. 20:385–388.
Sargent, T., Kalbhen, D. A., Shulgin, A. T., Stauffer, H., and Kusubov, N., 1975a, A potential new brain-scanning agent, 4-77Br-2,5-dimethoxyphenylisopropylamine (4-Br-DPIA), J. Neuc. Med. 16:243–245.
Sargent, T., Kalbhen, D. A., Shulgin, A. T., Braun, G., Stauffer, H., and Kusubov, N., 1975b, In vivo human pharmacodynamics of the psychodysleptic 4-Br-2,5-dimethoxy-phenylisopropylamine labelled with 82Br or 77Br, Neuropharmacology 14:165–174.
Sargent, T., Shulgin, A. T., and Kusubov, N., 1976, Quantitative measurement of demethylation of 14C-methoxy labeled DMPEA and TMA-2 in rats, Psychopharmacol. Commun. 2:199–206.
Sargent, T., III, Budinger, T. F., Shulgin, A. T., Braun, G., and Braun, U., 1977, Brain uptake of a radioiodine labeled psychotomimetic in dog and monkey, J. Biol. Psychiat. (submitted; presented at Soc. Biol. Psychiat. Meeting, Toronto, April, 1977).
Schneider, C. W., and Chenoweth, M. B., 1970, Effects of hallucinogenic and other drugs on the nest-building behavior of mice, Nature 225:1262–1263.
Schultes, R. E., 1972, An overview of hallucinogens in the Western Hemisphere, see Furst (1972), pp. 3-54.
Schultes, R. E., and Hofmann, A., 1973, The Botany and Chemistry of Hallucinogens, Charles C. Thomas, Springfield, Illinois.
Schweitzer, J. W., and Friedhoff, A. J., 1968, The metabolism of dimethoxyphenethylamine, a compound found in the urine of schizophrenics, Am. J. Psychiat. 124:1249–1253.
Schweitzer, J. W., and Friedhoff, A. J. 1970, Amphetamines in human urine: Rapid estimation by gas-liquid chromatography, Clin. Chem. 16:786–788.
Schweitzer, J. W., Friedhoff, A. J., Angrist, B. M., and Gershon, S., 1971, Excretion of p-methoxyamphetamine administered to humans, Nature 229:133–134.
Seiler, N., and Demisch, L., 1971, Oxidative metabolism of mescaline in the central nervous system. II. Oxidative deamination of mescaline and 2,3,4-trimethoxy-beta-phenethylamine by different mouse brain areas in vitro, Biochem. Pharm. 20:2485–2493.
Sen, N. P., and McGeer, P. L., 1964, 4-Methoxyphenylethylamine and 3,4-dimethoxyphenylethylamine in human urine, Biochem. Biophys. Res. Commun. 14:227–232.
Sepulveda, S., Valenzuela, R., and Cassels, B. K., 1972, Potential psychotomimetics. New bromoalkoxyamphetamines. J. Med. Chem. 15:413–415.
Severs, P. S., Dring, L. G., and Williams, R. T., 1976, Urinary metabolites of p-hydroxyamphetamine in man, rat, and guinea pig, Xenobiotica 6:345–353.
Shaler, R. C., and Padden, J. J., 1972, Identification of hallucinogens in illicit seizures. I. 2,5-Dimethoxyamphetamine, J. Pharm. Sci. 61:1851–1855.
Sherman, A. D., and Gál, E. M., 1976, Mass-spectrographic evidence of the conversion of p-chloroamphetamine to 3,4-dimethoxyamphetamine, Psychopharm. Commun. 2:421–427.
Shulgin, A. T., 1964a, Psychotomimetic amphetamines: Methoxy 3,4-dialkoxyamphetamines, Experientia 20:366–367.
Shulgin, A. T., 1964b, 3-Methoxy-4,5-methylenedioxy amphetamine, a new psychotomimetic agent, Nature 201:1120–1121.
Shulgin, A. T., 1966a, The six trimethoxyphenylisopropylamines (trimethoxyamphetamines), J. Med. Chem. 9:445–446.
Shulgin, A. T., 1966b, Possible implication of myristicin as a pyschotropic substance, Nature 210:380–384.
Shulgin, A. T., 1968, The ethyl homologs of 2,4,5-trimethoxyphenylisopropylamine, J. Med. Chem. 11:186–187.
Shulgin, A. T., 1970a, Chemistry and structure-activity relationships of the psychotomimetics, in Psychotomimetic Drugs (D. H. Efron, ed.), Raven Press, New York.
Shulgin, A. T., 1970b, 4-Alkyl-alpha-methyl phenethylamines and their pharmacologically acceptable salts, U.S. Patent 3,547,999.
Shulgin, A. T., 1971, Preliminary studies of the synthesis of nitrogen analogs of delta-1THC, Acta Pharm. Suecica 8:680–681.
Shulgin, A. T., 1973a, Mescaline: The chemistry and pharmacology of its analogs, Lloydia 36:46–58.
Shulgin, A. T., 1973b, Stereospecific requirements for hallucinogenisis, J. Pharm. Pharmacol. 25:271–272.
Shulgin, A. T., 1976a, Psychotomimetic agents in Psychopharmacological Agents, Vol. 4 (M. Gordon, ed.), Academic Press, New York.
Shulgin, A. T., 1976b, Abuse of the term “amphetamines,” Clin. Toxicol. 9:351–352.
Shulgin, A. T., 1976c, Profiles of psychedelic drugs. 2. TMA-2, J. Psychedelic Drugs 8:169.
Shulgin, A. T., and Carter, M. F., 1975, Centrally active phenethylamines, Psychopharmacol. Commun. 1:93–98.
Shulgin, A. T., and Dyer, D. C., 1975, Psychotomimetic phenylisopropylamines. V. 4-Alkyl-2,5-dimethoxyphenylisopropylamines, J. Med. Chem. 18:1201–1204.
Shulgin, A. T., and Nichols, D. E., 1977, Characterization of three new psychotomimetics, in Psychopharmacology of Hallucinogens (R. Stillman, ed.), Pergamon Press, New York.
Shulgin, A. T., and Sargent, T., 1967, Psychotropic phenylisopropylamines derived from apiole and dillapiole, Nature 215:1494–1495.
Shulgin, A. T., Bunnell, S., and Sargent, T., 1961, The psychotomimetic properties of 3,4,5-trimethoxyamphetamine, Nature 189:1011–1012.
Shulgin, A. T., Sargent, T., and Naranjo, C., 1966, Role of 3,4-dimethoxyphenethylamine in schizophrenia, Nature 212:1606–1607.
Shulgin, A. T., Sargent, T., and Naranjo, C., 1967, The chemistry and psychopharmacology of nutmeg and several related phenylisopropylamines, in The Ethnopharmacologic Search for Psychoactive Drugs (D. Efron, ed.), pp. 202-214, USGPO.
Shulgin, A. T., Sargent, T., and Naranjo, C., 1969, Structure-activity relationships of one-ring psychotomimetics, Nature 221:537–541.
Shulgin, A. T., Sargent, T., and Naranjo, C., 1971, 4-Bromo-2,5-dimethoxyphenylisopropylamine, a new centrally active amphetamine analog, Pharmacology 5:103–107.
Shulgin, A. T., Sargent, T., and Naranjo, C., 1973, Animal pharmacology and human psychopharmacology of 3-methoxy-4,5-methylenedioxyphenyliospropylamine (MMDA), Pharmacology 10:12–18.
Silva, M. T. A., and Calil, H. M., 1975, Screening hallucinogenic drugs. Systematic study of three behavioral tests, Psychopharmacologia 42:163–171.
Slotkin, J. S., 1956, The Peyote Religion, The Free Press, Glencoe, Illinois.
Slotta, K. H., and Heller, H., 1930, Über beta-Phenethylamine. I. Mezcalin-ahnlicher Substanzen, Chem. Ber. 63:3029–3044.
Slotta, K. H., and Müller, J., 1936, Über den Abbau des Mescalins und mescalinähnlicher Stoffe im Organismus, Z. Physiol. Chem. 238:14–22.
Smith, D. E., 1969, The psychotomimetic amphetamines with special reference to DOM (STP) toxicity, J. Psychedelic Drugs 2:37–41.
Smythies, J. R., and Levy, C. K., 1960, The comparative psychopharmacology of some mescaline analogs, J. Mental Sci. 106:531–536.
Smythies, J. R., Bradley, R. J., Johnson, V. S., Benington, F., Morin, R. D., and Clark, L., 1967a, Structure-activity relationship on of mescaline. III. The influence of the methoxy groups, Psychopharmacologia 10:379–387.
Smythies, J. R., Johnson, V. S., and Bradley, R. J., 1967b, Alteration by pretreatment with iproniazid and an inactive mescaline analogue of the behavioral change by mescaline, Nature 216:196–197.
Smythies, J. R., Johnson, V. S., Bradley, R. J., Benington, F., Morin, R. D., and Clark, L. C., 1967c, Some new behavior-disrupting amphetamines and their significance, Nature 216:128–129.
Smythies, J. R., Johnson, V. S., and Bradley, R. J., 1969, Behavioral models of psychosis, Br. J. Psychiat. 115:55–68.
Smythies, J. R., Benington, F., and Morin, R., 1970, The mechanism of action of hallucinogenic drugs on a possible serotonin receptor in the brain, Int. Rev. Neurobiol. 12:207–236.
Snyder, S. H., and Merril, C. R., 1965, A relationship between the hallucinogenic activity of drugs and their electronic configuration, Proc. Nat. Acad. Sci. 54:258–266.
Snyder, S. H., and Richelson, E., 1968, Psychedelic drugs: Steric factors that predict psychotropic activity, Proc. Nat. Acad. Sci. 60:206–213.
Snyder, S. H., Faillace, L. A., and Hollister, L. E., 1967, 2,5-Dimethoxy-4-methylamphetamine (STP): A new hallucinogenic drug, Science 158:669–670.
Snyder, S. H., Faillace, L. A., and Weingartner, H., 1968, DOM (STP), A new hallucinogenic drug, and DOET: Effects in normal subjects, Am. J. Psychiat. 125:357–364.
Snyder, S. H., Faillace, L. A., and Weingartner, H., 1969, A new psychotropic agent. Psychological and physiological effects of 2,5-dimethoxy-4-ethyl amphetamine (DOET) in man, Arch. Gen. Psychiat. 21:95–101.
Snyder, S. H., Weingartner, H., and Faillace, L. A., 1971, DOET (2,5-dimethoxy-4-ethylamphetamine), a new psychotropic drug. Effects of varying doses in man, Arch. Gen. Psychiat. 24:50–55.
Snyder, S. H., Unger, S., Blatchley, R., and Barfknecht, C. F., 1974, Stereospecific actions of DOET (2,5-dimethoxy-4-ethylamphetamine) in man, Arch. Gen. Psychiat. 31:103–106.
Späth, E., and Bruck, J., 1937, Über ein neues Alkaloid aus den Mezcal Buttons, Chem. Ber. 70:2446–2450.
Späth, E., and Bruck, J., 1938, N-Acetylmezcalin als Inhaltsstoff der Mezcal Buttons, Chem. Ber. 71:1275–1276.
Stone, C. A., 1963, Composition hypotensive et son utilisation, Brev. Belge, #633,963.
Sugasawa, S., and Hino, T., 1954, Synthesis of 1-(3,4-methylenedioxyphenyl)-3,5-dimethyl-7,8-methylenedioxyisoquinoline, Pharm. Bull. (Japan) 2:242–246.
Sung, M-T., and Parker, J. A., 1972, Amphetamines: Correlation of activity with stability of molecular complexes, Proc. Nat. Acad. Sci. 69:1346–1347.
Sung, M-T., and Parker, J. A., 1974, Molecular complexes between methoxyamphetamines and riboflavin derivatives, Z. Naturforsch. 29:122–127.
Tacker, M., Creaven, P. J., and McIsaac, W. M., 1969, Preliminary observations on the metabolism of 3H-2,5-dimethoxy-4-methylamphetamine (STP, DOM) in Drug Dependence (R. T. Harris, W. M. McIsaac, and C. R. Schuster, eds.), pp. 21–23, Univ. of Texas Press, Austin, Texas.
Tansey, L. W., Estevez, V. S., and Ho, B. T., 1975, Metabolic studies of 2,5-dimethoxy-4-ethylamphetamine (DOET) in rats, Proc. West. Pharmacol. Soc. 18:362.
Todd, J. S., 1969, Thin layer chromatography analysis of Mexican populations of Lophophora (cactaceae), Lloydia 32:395–398.
Tozman, S., Schweitzer, J. W., and Friedhoff, A. J., 1972, Demethylation of (4-methoxy-14C)-N-acetyl-3,4-dimethoxyphenethylamine in schizophrenics—A preliminary study, Life Sci. 11:1069–1078.
Tseng, L.-F., Menon, M. K., and Loh, H. H., 1976, Comparative actions of monomethoxyamphetamines on the release and uptake of biogenic amines in brain tissue, J. Pharm. Exp. Ther. 197:263–271.
Turek, I. S., Soskin, R. A., and Kurland, A. A., 1974, Methylenedioxyamphetamine (MDA) subjective effects, J. Psychedelic Drugs 6:7–14.
Turner, W. J., and Heyman, J. J., 1960, The presence of mescaline in Opuntia cylindrica, J. Org. Chem. 25:2250–2251.
Uyeno, E. T., 1968, Hallucinogenic compounds and swimming response, J. Pharm. Exp. Ther. 159:216–221.
Uyeno, E. T., Otis, L. S., and Mitoma, C., 1968, Behavioral evaluation of hallucinogenic trimethoxyamphetamines in squirrel monkeys (Saimiri sciureus), Commun. Behav. Biol. 1:83–90.
van Praag, H. M., and Korf, J., 1976, 4-Chloroamphetamines. Chance and trend in the development of new antidepressants, Psychopharmacol. Bull. 12(3):64–74.
van Praag, H. M., Schut, T., Bosman, E., and van den Bergh, R., 1971, A comparative study of the therapeutic effects of some 4-chlorinated amphetamine derivatives in depressed patients, Psychopharmacologia 20:66–76.
Verster, J., and van Praag, H. M., 1970, A comparative investigation of methylamphetamine and 4-chloro-N-methylamphetamine in healthy test subjects, Pharmako-psychiatry 3:239–248.
Vojtechovsky, M., and Krus, D., 1967, Psychotropic effect of mescaline-like drugs, Acta New. Sup., 381-383.
von Studnitz, W., and Nyman, G. E., 1965, Excretion of 3,4-dimethoxyphenethylamine in schizophrenia, Acta Psychiat. Scand. 41:117–121.
Weil, A. T., 1967, Nutmeg as a psychoactive drug, in The Ethnopharmacologic Search for Psychoactive Drugs (D. Efron, ed.), pp. 188-201, USGPO.
Weingartner, H., Snyder, S. H., Faillace, L. A., and Markley, H., 1970, Altered free associations: Some cognitive effects of DOET (2,5-dimethoxy-4-ethylamphetamine), Behav. Sci. 15:297–303.
Weingartner, H., Snyder, S. H., and Faillace, L. A., 1971, DOM (STP). A new hallucinogenic drug: Specific perceptual changes, J. Clin. Pharmacol. 11:103–111.
Weinkam, R. J., Gal, J., Callery, P., and Castagnoli, N., Jr., 1976, Application of chemical ionization mass spectrometry to the study of stereoselective in vitro metabolism of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane, Anal. Chem. 48:203–209.
Wenner, W., 1951, Hydroxyphenylisopropylamines containing nuclear methyl groups, J. Org. Chem. 16:457–460.
Winter, J. C., 1973, A comparison of the stimulus properties of mescaline and 2,3,4-trimethoxyphenylethylamine, J. Pharm. Pharmacol. 185:101–107.
Yensen, R., DiLeo, F. B., Rhead, J. C., Richards, W. A., Soskin, R. A., Turek, B., and Kurland, A. A., 1976, MDA-assisted psychotherapy with neurotic outpatients: A pilot study, J. Nerv. Mental Dis. 163:233–245.
Yunger, L. M., McMaster, S. E., and Harvey, J. A., 1974, Neurotoxic effects of p-chloroamphetamine and 5-hydroxyindoleacetic acid in brain, Pharmacologist 16:244.
Zweig, J. S., and Castagnoli, N., Jr., 1974, Chemical conversion of the psychotomimetic amine 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane to 5-hydroxy-2,6-dimethylindole, J. Med. Chem. 17:747–749.
Zweig, J. S., and Castagnoli, N., Jr., 1975, Metabolic O-demethylation of the psychotomimetic amine 1-(2,5-dimethoxy-4-methylphenyl)2-aminopropane, Psychopharmacol. Comm. 1:359–371.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1978 Plenum Press, New York
About this chapter
Cite this chapter
Shulgin, A.T. (1978). Psychotomimetic Drugs: Structure-Activity Relationships. In: Iversen, L.L., Iversen, S.D., Snyder, S.H. (eds) Stimulants. Handbook of Psychopharmacology, vol 11. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-0510-2_6
Download citation
DOI: https://doi.org/10.1007/978-1-4757-0510-2_6
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-0512-6
Online ISBN: 978-1-4757-0510-2
eBook Packages: Springer Book Archive
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
